Literature DB >> 3463510

Comparative pharmacokinetic study of adriamycin and 4'epi-adriamycin after their simultaneous intravenous administration.

S Eksborg, U Stendahl, U Lönroth.   

Abstract

The plasma pharmacokinetics of adriamycin and 4'epi-adriamycin have been studied in 6 patients with ovarian carcinoma after simultaneous intravenous administration of equal amounts of the two anthracyclines. A highly selective liquid chromatographic analytical method permitted quantification of plasma concentrations of the two drugs as well as their corresponding 13-hydroxy metabolites. The plasma concentrations of each drug followed a three-compartment open model, with great interindividual variation in the pharmacokinetic parameters. On average, the area under the plasma concentration time curve (AUC) and the maximum plasma concentration (Cmax) were 1.6- and 1.2-times larger for adriamycin than for 4'epi-adriamycin. 4'Epi-adriamycin was eliminated faster than adriamycin by 4 of the 6 patients, the average terminal half-life of the latter being 1.4-times longer. The plasma concentrations of the 13-hydroxy metabolites did not exceed 20 ng/ml. Their AUC values averaged 23% of those of the intact drugs.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3463510     DOI: 10.1007/BF00542426

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Adriamycin-a review.

Authors:  S K Carter
Journal:  J Natl Cancer Inst       Date:  1975-12       Impact factor: 13.506

2.  Liquid chromatography in anticancer drug research with special reference to anthraquinone glycosides.

Authors:  S Eksborg; H Ehrsson
Journal:  J Pharm Biomed Anal       Date:  1984       Impact factor: 3.935

3.  Pharmacokinetic study of i.v. infusions of adriamycin.

Authors:  S Eksborg; H S Strandler; F Edsmyr; I Näslund; P Tahvanainen
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  Pharmacokinetic studies of 4'-epi-doxorubicin in cancer patients with normal and impaired renal function and with hepatic metastases.

Authors:  C M Camaggi; E Strocchi; V Tamassia; A Martoni; M Giovannini; G Lafelice; N Canova; D Marraro; A Martini; F Pannuti
Journal:  Cancer Treat Rep       Date:  1982-10

5.  Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer.

Authors:  J Robert; P Vrignaud; T Nguyen-Ngoc; A Iliadis; L Mauriac; P Hurteloup
Journal:  Cancer Treat Rep       Date:  1985-06

6.  Distribution of adriamycin in cancer patients: tissue uptakes, plasma concentration after IV and hepatic IA administration.

Authors:  Y T Lee; K K Chan; P A Harris; J L Cohen
Journal:  Cancer       Date:  1980-05-01       Impact factor: 6.860

7.  Pharmacokinetics of 4'-epi-doxorubicin in man.

Authors:  H Weenen; J Lankelma; P G Penders; J G McVie; W W ten Bokkel Huinink; M M de Planque; H M Pinedo
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

8.  Cross-over study of pharmacokinetics and haematological toxicity of 4'-epi-doxorubicin and doxorubicin in cancer patients.

Authors:  A Martini; E Moro; M A Pacciarini; V Tamassia; N Natale; E Piazza
Journal:  Int J Clin Pharmacol Res       Date:  1984

9.  Adriamycin and methyl-CCNU combination therapy in hepatocellular carcinoma: clinical and pharmacokinetic aspects.

Authors:  R T Chlebowski; K K Chan; M J Tong; J M Weiner; V M Ryden; J R Bateman
Journal:  Cancer       Date:  1981-09-01       Impact factor: 6.860

10.  Clinical toxicity of 4'-epi-doxorubicin (epirubicin).

Authors:  F Ganzina; N Di Pietro; O Magni
Journal:  Tumori       Date:  1985-06-30
View more
  15 in total

1.  Metabolism of epirubicin to glucuronides: relationship to the pharmacodynamics of the drug.

Authors:  J Robert; M David; C Granger
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters.

Authors:  J M Jacquet; F Bressolle; M Galtier; M Bourrier; D Donadio; J Jourdan; J F Rossi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement.

Authors:  P Jakobsen; L Bastholt; M Dalmark; P Pfeiffer; D Petersen; S B Gjedde; E Sandberg; C Rose; O S Nielsen; H T Mouridsen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  Pharmacokinetics of 4' epi-adriamycin after morning and afternoon intravenous administration.

Authors:  S Eksborg; U Stendahl; K Antila
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

Review 5.  Clinical pharmacokinetics of drugs used in the treatment of breast cancer.

Authors:  V J Wiebe; C C Benz; M W DeGregorio
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

Review 6.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

7.  Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study.

Authors:  C M Camaggi; E Strocchi; P Carisi; A Martoni; B Melotti; F Pannuti
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 8.  Epirubicin. Clinical pharmacology and dose-effect relationship.

Authors:  J Robert
Journal:  Drugs       Date:  1993       Impact factor: 9.546

9.  Pharmacokinetics of epirubicin in man. Non-influence of alpha interferon.

Authors:  S Eksborg; K Mattson
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

10.  Epirubicin as a single agent therapy for the treatment of breast cancer--a pharmacokinetic and clinical study.

Authors:  S Eksborg; L Hardell; N O Bengtsson; M Sjödin; B Elfsson
Journal:  Med Oncol Tumor Pharmacother       Date:  1992
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.